Skip to the answer

Remdesivir Injection

Remdesivir is an antiviral medication used intravenously to treat COVID-19 in hospitalized patients and in non-hospitalized patients at high risk of getting seriously ill.

Brand name Veklury
Drug class Sars-cov-2 Nucleotide Analog Rna Polymerase Inhibitor
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Remdesivir Injection at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Remdesivir (Veklury) is an IV antiviral that mimics a building block the virus needs to copy its genetic material, stalling its ability to reproduce; on the market since about 2020, it is a standard hospital treatment for COVID-19 and is also given as a short outpatient course to adults and children at high risk of severe illness. Most people tolerate it well; nausea is the side effect people notice, and liver enzymes can rise, so blood tests are checked before and during treatment. The real risk is a serious allergic or infusion reaction, even anaphylaxis (a life-threatening whole-body reaction), usually during or within an hour of the drip.

Clinical pearls

  • Start as soon as possible after diagnosis; course length depends on how sick you are and whether you are hospitalized.
  • Do not combine it with chloroquine or hydroxychloroquine, since they may weaken remdesivir’s effect against the virus.
  • Expect to stay at least an hour after each infusion so staff can catch and treat an allergic reaction.
  • Report yellow skin or eyes, dark urine, or stomach pain, since rising liver enzymes may mean remdesivir needs stopping.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asInjection
Earliest FDA record2020
Companies listing it with the FDA1
FDA label last updatedJul 29, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Remdesivir Injection, written from its FDA label.

What Remdesivir Injection is used for

▾

Remdesivir (Veklury) is an antiviral approved for the treatment of COVID-19 in a broad range of patients. All uses below apply to Veklury given by intravenous infusion.

  • Treatment of COVID-19 in hospitalized adults
  • Treatment of COVID-19 in hospitalized pediatric patients from birth to under 18 years of age who weigh at least 1.5 kg
  • Treatment of mild-to-moderate COVID-19 in non-hospitalized adults who are at high risk for progression to severe COVID-19, including hospitalization or death
  • Treatment of mild-to-moderate COVID-19 in non-hospitalized pediatric patients (birth to under 18 years, weighing at least 1.5 kg) at high risk for severe disease

How Remdesivir Injection works

▾

Remdesivir is a nucleotide analog — a molecule that closely resembles one of the natural building blocks the SARS-CoV-2 virus uses to copy its genetic material (RNA). Once inside the body, remdesivir is converted into its active form, which gets incorporated into the virus's copying machinery. This effectively jams the process, preventing the virus from making new copies of itself and slowing the spread of infection.

Remdesivir Injection dosage

▾

Veklury is given once daily by intravenous (IV) infusion over 30 to 120 minutes. It is always prepared and administered by healthcare professionals — patients do not take it at home. Treatment should start as soon as possible after a COVID-19 diagnosis is confirmed.

  • Hospitalized patients on a ventilator or ECMO: typically up to 10 days of treatment
  • Hospitalized patients not on a ventilator or ECMO: typically 5 days, possibly extended to 10 days if improvement is slow
  • Non-hospitalized high-risk patients: typically a 3-day course, started within 7 days of symptom onset
  • Dosing in children is based on body weight — your child's care team will calculate the right amount

Dosing details from the FDA-approved label

From the Remdesivir Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Adults and pediatric patients weighing at least 40 kg
    • A single loading dose of VEKLURY 200 mg on Day 1 via intravenous infusion followed by once-daily maintenance doses of VEKLURY 100 mg from Day 2 via intravenous infusion
    • Administer via intravenous infusion over 30 to 120 minutes
  • Pediatric patients less than 28 days old and at least 1.5 kg
    • VEKLURY 2.5 mg/kg on Day 1 (loading dose)
    • VEKLURY 1.25 mg/kg once daily from Day 2 (maintenance dose)
    • Weight-based dosing for patients weighing 1.5 kg to less than 40 kg
  • Pediatric patients at least 28 days old and 3 kg to less than 40 kg
    • VEKLURY 5 mg/kg on Day 1 (loading dose)
    • VEKLURY 2.5 mg/kg once daily from Day 2 (maintenance dose)
    • Weight-based dosing
  • Pediatric patients at least 28 days old and 1.5 kg to less than 3 kg
    • The label lists this group in the same row as the 3 kg to less than 40 kg group, with VEKLURY 5 mg/kg on Day 1 and 2.5 mg/kg once daily from Day 2 (flattened table)
    • Weight-based dosing
  • Hospitalized patients requiring invasive mechanical ventilation and/or ECMO
    • Recommended total treatment duration is 10 days
    • Initiate as soon as possible after diagnosis of symptomatic COVID-19
  • Hospitalized patients not requiring invasive mechanical ventilation and/or ECMO
    • Recommended treatment duration is 5 days
    • If no clinical improvement, treatment may be extended for up to 5 additional days
    • Maximum: total treatment duration of up to 10 days
    • Initiate as soon as possible after diagnosis of symptomatic COVID-19
  • Non-hospitalized patients with mild-to-moderate COVID-19 at high risk for progression to severe COVID-19, including hospitalization or death
    • Recommended total treatment duration is 3 days
    • Initiate as soon as possible after diagnosis and within 7 days of symptom onset
  • Renal impairment
    • No dosage adjustment of VEKLURY is recommended in patients with any degree of renal impairment, including patients on dialysis
    • May be administered without regard to the timing of dialysis
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Testing: In all patients, before starting VEKLURY and during treatment as clinically appropriate, perform hepatic laboratory testing. Assess prothrombin time before starting VEKLURY and monitor as clinically appropriate. ( 2.2 ) Recommended dosage: Adults and pediatric patients weighing at least 40 kg: a single loading dose of VEKLURY 200 mg on Day 1 followed by once-daily maintenance doses of VEKLURY 100 mg from Day 2 via intravenous infusion. ( 2.3 ) Pediatric patients (birth to less than 18 years of age) weighing 1.5 kg to less than 40 kg: Recommended dosage is based on weight. Refer to Table 1 of the full prescribing information for specific dosing guidelines based on body weight. ( 2.3 ) Hospitalized patients: The treatment course of VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 has been made. ( 2.3 ) For hospitalized patients requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 10 days. ( 2.3 ) For hospitalized patients not requiring invasive mechanical ventilation and/or ECMO, the recommended treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. ( 2.3 ) Non-hospitalized patients: The treatment course of VEKLURY should be initiated as soon as possible after diagnosis of symptomatic COVID-19 has been made and within 7 days of symptom onset. ( 2.3 ) For non-hospitalized patients diagnosed with mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19, including hospitalization or death, the recommended total treatment duration is 3 days ( 2.3 ). Renal impairment: No dosage adjustment of VEKLURY is recommended in patients with any degree of renal impairment, including those on dialysis. ( 2.4 ) Administer VEKLURY via intravenous (IV) infusion over 30 to 120 minutes. ( 2.5 ) Dose preparation and administration: Refer to the full prescribing information for further details. ( 2.5 ) Storage of prepared dosages: VEKLURY contains no preservative.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Remdesivir Injection side effects

▾

The most commonly reported side effects with Veklury include:

Common side effects

  • Nausea
  • Elevated ALT (a liver enzyme) on blood tests
  • Elevated AST (another liver enzyme) on blood tests
  • Infusion-related reactions (during or shortly after the IV drip)
  • Rash
  • Increased liver enzyme levels (transaminase elevations)

When to get medical help

  • Call for help immediately if you have trouble breathing, swelling of the face or throat, severe drop in blood pressure, rapid or slow heart rate, or fever during or after the infusion — these can be signs of a serious allergic (anaphylactic) reaction.
  • Tell your doctor right away if you develop signs of liver problems: yellowing of the skin or eyes, dark urine, stomach pain, or unusual fatigue.
  • Alert your care team if you notice a new or worsening rash, chills, dizziness, or feel unwell during the infusion.

More seriously, some people experience a severe allergic reaction (anaphylaxis) during or within an hour after infusion — with symptoms like low blood pressure, rapid or slow heart rate, difficulty breathing, swelling, or rash. This is why Veklury is given only where emergency treatment is immediately available. Liver enzyme levels can also rise significantly; your care team monitors these throughout your treatment.

Remdesivir Injection warnings and precautions

▾
  • Serious allergic and infusion-related reactions, including anaphylaxis: These can occur during or within one hour of the infusion. Signs include low or high blood pressure, fast or slow heart rate, low oxygen levels, fever, trouble breathing, swelling, rash, nausea, sweating, or shivering. Veklury must only be given where staff can treat these reactions immediately. You will be watched during and for at least one hour after each infusion.
  • Liver enzyme elevations: Remdesivir has been associated with increases in liver enzymes (transaminases). Liver labs are checked before you start and during treatment. If enzymes rise too high, or if you develop symptoms of liver inflammation, treatment may be stopped.
  • Reduced effectiveness with certain malaria drugs: Combining Veklury with chloroquine phosphate or hydroxychloroquine sulfate is not recommended — these drugs may block remdesivir from working properly inside cells.

Remdesivir Injection interactions

▾

There are a small number of important drug interactions to be aware of with Veklury:

  • Chloroquine phosphate or hydroxychloroquine sulfate: Do not use these together with Veklury. Lab studies show they may prevent remdesivir from being converted to its active form inside cells, reducing its antiviral effect.
  • CYP3A4 inducers and certain drug transporters: Based on available studies, no clinically significant interactions are expected with drugs that affect the CYP3A4 enzyme system or certain drug transport proteins (OATP1B1/1B3, P-gp) — but always tell your care team every medication you take.

Interactions listed in the FDA-approved label

From the Remdesivir Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Chloroquine phosphate or hydroxychloroquine sulfate: Potential antagonism based on data from cell culture experiments. Concomitant use with VEKLURY is not recommended.
  • Inducers of cytochrome P450 (CYP) 3A4: No clinically significant drug interactions are expected based on drug interaction studies.
  • Inhibitors of OATP1B1/1B3 and P-glycoprotein (P-gp): No clinically significant drug interactions are expected based on drug interaction studies.
  • CYP3A substrates (effect of VEKLURY on other drugs): VEKLURY is a weak inhibitor of CYP3A based on drug interaction studies.
  • OATP1B1/1B3 (effect of VEKLURY on other drugs): VEKLURY does not inhibit OATP1B1/1B3.
Read the label’s full interactions text

7 DRUG INTERACTIONS 7.1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended [see Warnings and Precautions (5.3) and Microbiology (12.4) ]. Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) [see Clinical Pharmacology (12.3) ]. 7.2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 [see Clinical Pharmacology (12.3) ].

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿140 supplements and herbs with documented Remdesivir Injection interactions, ranked by severity Check Remdesivir Injection against a supplement or herb →

Before taking Remdesivir Injection

▾
  • Allergy to remdesivir or its ingredients: Veklury is contraindicated if you have had a serious allergic reaction to it before.
  • Liver disease or abnormal liver tests: Liver function must be checked before and during treatment.
  • Kidney disease or dialysis: No dose change is required, but your care team should know about any kidney problems. Veklury can be given without adjusting for the timing of dialysis.
  • Pregnancy: Available data have not shown a clear risk of birth defects or miscarriage from use in the second or third trimester. Data on first-trimester exposure are limited. COVID-19 itself poses serious risks during pregnancy. Discuss the benefits and risks with your doctor.
  • Breastfeeding: Remdesivir and its active metabolite have been detected in human breast milk. Weigh the benefits of breastfeeding against any potential risks with your healthcare provider. Also follow clinical guidelines to avoid exposing your infant to COVID-19.
  • Children: Veklury is approved for children from birth to under 18 years of age who weigh at least 1.5 kg. Dosing is based on the child's weight.
  • Currently taking chloroquine or hydroxychloroquine: Tell your care team — these should not be used at the same time as Veklury.

Remdesivir Injection overdose

▾

There is no human experience with a Veklury overdose. If too much is given, there is no specific antidote. Treatment would focus on supportive care — monitoring vital signs and watching the patient's overall condition closely until it resolves.

What Remdesivir Injection does in the body

▾

Remdesivir works against SARS-CoV-2 by interfering with the virus's RNA-copying process. At three times the maximum recommended dose, remdesivir did not cause meaningful changes in the QTc interval — a measure of the heart's electrical rhythm — so clinically significant heart rhythm effects are not expected at normal doses. The full relationship between remdesivir blood levels and how well it works is not yet fully established.

How your body processes Remdesivir Injection

▾

Remdesivir is given intravenously and reaches peak blood levels very quickly — typically within about 40 minutes of the start of infusion. It is broken down mainly in the liver and blood cells into active and inactive metabolites; its own half-life (how long it takes the body to clear half the drug) is about 1 hour, though its key active metabolite (GS-441524) has a much longer half-life of around 27 hours. Most of the drug and its breakdown products are eliminated through urine and metabolism, and the pharmacokinetics are similar in pregnant and non-pregnant individuals and are not meaningfully affected by sex or race.

How to store Remdesivir Injection

▾

Store VEKLURY for injection, 100 mg vials below 30°C (below 86°F) until required for use. stored up to 24 hours at room temperature (20°C to 25°C ) prior to administration or 48 hours at refrigerated temperature (2°C to 8°C ).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

140

Supplements & herbs that interact with Remdesivir Injection

140 supplements and herbal products have documented interactions with Remdesivir Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 7
  • Moderate · 105
  • Minor · 28
AMERICAN HELLEBORE Major ARSENIC Major CESIUM Major EPHEDRA Major GRAPEFRUIT Major SIDA CORDIFOLIA Major ST. JOHN'S WORT Major ACACIA RIGIDULA Moderate +132 more
Every supplement checked against Remdesivir Injection — ranked by severity The full interaction hub: 7 major · 105 moderate · 28 minor · every one linked to its full report. Check Remdesivir Injection against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Remdesivir Injection: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Remdesivir Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is Veklury and why has my doctor prescribed it?

▾
Veklury is the brand name for remdesivir, an antiviral medication that fights the SARS-CoV-2 virus — the one that causes COVID-19. Your doctor prescribed it either because you're hospitalized with COVID-19, or because you have mild-to-moderate COVID-19 but are at high risk of getting seriously ill. It works by interfering with the virus's ability to copy itself, which can help slow the infection.

How will I receive this medication — do I take a pill?

▾
No, Veklury isn't a pill. It's given as an IV infusion — a slow drip directly into a vein — by a nurse or other healthcare provider. Each infusion takes anywhere from 30 minutes to 2 hours, and you'll receive it once a day. You can't take it at home; it must be given in a clinic or hospital where staff can respond if a reaction occurs.

How many days will I need to receive it?

▾
That depends on your situation. If you're not hospitalized and your doctor is treating you early to prevent you from getting worse, a 3-day course is typical — and it needs to start within 7 days of your symptoms beginning. If you're in the hospital and not on a breathing machine, the usual course is 5 days, sometimes extended to 10 if needed. If you're on a ventilator or ECMO (a heart-lung bypass machine), treatment may run up to 10 days. Your care team will set the schedule that's right for you.

What side effects should I watch for during or after the infusion?

▾
The most common side effects are nausea and changes in liver enzyme levels on blood tests — your team monitors those labs throughout. More importantly, some people have infusion-related or allergic reactions during or right after the drip, with symptoms like difficulty breathing, swelling, a rash, a racing or slow heart, dizziness, or chills. That's exactly why you're watched during and for at least an hour after each infusion — if anything feels off, tell the nurse immediately.

I'm pregnant — is it safe for me to receive Veklury?

▾
This is a really important conversation to have with your doctor, and the short answer is: available data have not shown a clear risk of birth defects or miscarriage from Veklury use in the second or third trimester, and blood levels of the drug are similar in pregnant and non-pregnant individuals. However, data from the first trimester are limited. On the other side, untreated COVID-19 during pregnancy carries its own serious risks. Your doctor will weigh those risks and benefits with you to make the best decision.

I also take hydroxychloroquine — is that okay with Veklury?

▾
You need to tell your care team about this right away. Hydroxychloroquine (and its related drug chloroquine) should not be used at the same time as Veklury. Lab studies suggest these drugs can block remdesivir from being converted into the active form it needs to fight the virus — essentially making Veklury less effective. Your team will decide how to manage this before starting treatment.

Is Remdesivir Injection available over the counter?

▾
No. Remdesivir Injection is a prescription medicine: every Remdesivir Injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Remdesivir Injection first available?

▾
The earliest FDA record we hold for Remdesivir Injection is from 2020: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Remdesivir Injection was first used.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Remdesivir Injection on HelloPharmacist

📊Remdesivir Injection supplement interactions140 checked — ranked by severity 🌿Drug & Supplement CheckerRemdesivir Injection vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Remdesivir Injection NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Remdesivir Injection Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Remdesivir Injection forms and strengths (how it comes)

Remdesivir Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Injection

By injection · Into a vein
Brands Veklury
How this form is used
What it may be used for
  • Veklury is used intravenously to treat COVID-19 in hospitalized adults and children (from birth, weighing at least 1.5 kg).
  • Veklury is used intravenously to treat mild-to-moderate COVID-19 in non-hospitalized adults and children at high risk of serious illness or death from COVID-19.
Important instructions
  • Veklury is given only by intravenous infusion — never by mouth or any other route.
  • Veklury infusions are administered over 30 to 120 minutes, once daily, in a healthcare setting.
  • Veklury for injection must be reconstituted and then diluted in a sodium chloride (saline) infusion bag before use — this is done by healthcare staff.
  • Veklury must be administered in a setting where staff can immediately treat severe infusion or allergic reactions; patients are monitored during and for at least one hour after each infusion.
Available strengths 2 strengths
5 mg/mL 100 mg
7 FDA-listed product records ⓘ

Remdesivir Injection on the U.S. market: products, makers and brands

How Remdesivir Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 1 Remdesivir Injection product record with the FDA, mostly as injection; the earliest marketing or approval year on record is 2020. Brand names on the directory include Veklury; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names
1
FDA-listed product records ⓘ
2020
Earliest FDA record ⓘ

How widely Remdesivir Injection is used (Medicaid data)

A general measure of how commonly Remdesivir Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Remdesivir Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

1,078
Medicaid prescriptions filled (Q1–Q4 2025)
$858,427 gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Remdesivir Injection prescribed? Of the 1,601 medications we measure, Remdesivir Injection ranks #1,271 by Medicaid prescriptions — more than 21% of them.

Where Remdesivir Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #1,271 of 1,601
#1,266 Amphotericin B Injecti... 1,153 Rx #1,267 Vismodegib 1,149 Rx #1,268 Cefiderocol Injection 1,141 Rx #1,269 Anagrelide 1,137 Rx #1,270 Zidovudine 1,095 Rx #1,271 Ravulizumab-cwvz Injec... 1,078 Rx #1,272 Remdesivir Injection 1,078 Rx #1,273 Maraviroc 1,074 Rx #1,274 Olodaterol Oral Inhala... 1,072 Rx #1,275 Degarelix Injection 1,065 Rx #1,276 Ganaxolone 1,063 Rx

Utilization by Remdesivir Injection product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

remdesivir 100 MG Injection

1,078 Medicaid prescriptions (Q1–Q4 2025) 100% of Remdesivir Injection prescriptions shown $858,427 gross reimbursement (before rebates) ≈ $796 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2284960

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Remdesivir Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 3 listed Remdesivir Injection NDCs with Medicaid activity.

Compare Remdesivir Injection products

A representative set of FDA-listed product records for Remdesivir Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
100 mg Intravenous Gilead Sciences, Inc. NDA View NDC →

Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Remdesivir Injection NDCs →

Remdesivir Injection recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list 2 Remdesivir recalls since July 2021. None of them is still listed as ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Class I Sep 19, 2024 · Terminated · Gilead Sciences, Inc.
Presence of Particulate Matter: Presence of glass particle.
  • Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2 Lots: Lot: 47035CFA, Exp. 11/2025 FDA record D-0005-2025 →
Class I Dec 3, 2021 · Terminated · Gilead Sciences, Inc.
Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.
  • Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2 Lots: Lots: 2141001-1A, 2141002-1A, Exp. 01/2024 FDA record D-0299-2022 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Remdesivir Injection RxCUI 2284718 1 dose form · 2 strengths
  1. Dose form (SCDF) Injection RxCUI 2284959 In current FDA listings
    Clinical drug / strength (SCD) 20 ML remdesivir 5 MG/ML RxCUI 2367758 100 MG RxCUI 2284960

Look up RxCUI 2284718 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Remdesivir Injection brand names

Remdesivir Injection is sold under one brand name in the FDA directory — Veklury. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Veklury

Who makes Remdesivir Injection: manufacturers and labelers

One company lists Remdesivir Injection products with the FDA. By number of product records, the largest are Gilead Sciences, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Gilead Sciences, Inc. 1

Remdesivir Injection drug class (RxNorm)

Remdesivir Injection belongs to the SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor class.

Pharmacologic class SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor
Drug family (ATC) Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Remdesivir Injection page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jul 29, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Remdesivir Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Remdesivir Injection after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
1
Finished products in the current FDA directory
1
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Gilead Sciences, Inc.
Linked label effective
Jul 29, 2026
Composite sections available
22
Linked SPL Set ID
c0978fa8-53ff-4ca2-82a7-567fd3e958ca
Linked SPL Document ID
24078e66-bb6a-4aa3-a748-30762b6416af
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Gilead Sciences, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →